GSE185937
Impact of SLC-0111 (U-104) on HUH6 hepatoblastoma cell transcriptome in normoxic and hypoxic conditions
Carbonic anhydrase 9 (CAIX) is a transmembrane metalloenzyme whose main function is to maintain the acid-base balance of the cell and hypoxic condition induces its expression. Solid tumors often exhibit regions with low oxygen content in areas where the blood supply is insufficient. CAIX is overexpressed in multiple solid tumors, including hepatoblastoma, the most frequent childhood liver malignancy. SLC-0111 is a commercially available CAIX inhibitor that is currently passed Phase I clinical trial on solid tumors. In this study we assessed the impact of SLC-0111 on transcriptomic changes of HUH6 hepatoblastoma cell line cells in both normoxic and hypoxic condition. Overall design: HUH6 cells were treated with CAIX/XII inhibitor SLC-0111 (U-104) under normoxic or hypoxic conditions for 48 h. Cells were lysed and RNA was extracted. RNA sequencing was utilized to define transcriptomic changes caused by SLC-0111 treament in normoxia and hypoxia. In each group, four technical replicates were sequenced.